Table 3.

Microbiological and therapeutical features and outcomes of each type of infection treated with CFD.

Variables	HAPs	cUTIs	cIAIs	SSTIs	Osteomyelitis	CNS Infections	BSIs
Patients	n = 17	n = 5	n = 8	n = 9	n = 3	n = 2	n = 18
Bacterial isolates
Acinetobacter baumannii	13 (76.5)	3 (60.0)	6 (75.0)	8 (88.9)	2 (66.7)	2 (100)	15 (83.3)
Klebsiella pneumoniae	2 (11.8)	2 (40.0)	5 (62.5)	3 (33.3)	0 (0)	0 (0)	5 (27.8)
Pseudomonas aeruginosa	2 (11.8)	0 (0)	0 (0)	2 (22.2)	1 (33.3)	0 (0)	2 (11.1)
Escherichia coli	2 (11.8)	1 (20.0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5.6)
Stenotrophomonas maltophilia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5.6)
Polymicrobial isolates	3 (17.6)	1 (20.0)	3 (37.5)	3 (33.3)	0 (0)	0 (0)	0 (0)
No isolates	1 (5.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Therapy
Days of therapy, median (IQR)	8 (2–14)	10 (7–10)	10 (4–24)	11 (8–22)	32 (24–37)	12 (8–16)	9 (7–18)
Monotherapy regimen	15 (88.2)	5 (100)	4 (50.0)	6 (66.7)	2 (66.7)	1 (50.0)	14 (77.8)
Combination therapy regimen	2 (11.8)	0 (0)	4 (50.0)	3 (33.3)	1 (33.3)	1 (50.0)	4 (22.2)
Outcomes
Microbiological eradication at EOT	15 (88.2)	5 (100)	5 (62.5)	8 (88.9)	2 (66.7)	1 (50.0)	14 (77.8)
Clinical cure at EOT	5 (29.4)	4 (80.0)	3 (37.5)	8 (88.9)	2 (66.7)	1 (50.0)	9 (50.0)
Clinical response in first 72 h *	11 (64.7)	4 (80.0)	6 (75.0)	8 (88.9)	3 (100)	2 (100)	16 (88.9)
30-D all-causes mortality	9 (52.9)	0 (0)	5 (62.5)	1 (11.1)	1 (33.3)	2 (100)	8 (44.4)

Where not otherwise defined, results are presented as the number of patients and their (%) on total. HAP = hospital-acquired pneumonia; cIAI = complicated intrabdominal infections; cUTI = complicated urinary-tract infections; SSTI = soft-skin tissues infections; CNS = central nervous system; BSI = bloodstream infection; IQR = interquartile range; EOT = end of therapy; * see text; 30-D = thirty-days.